Pneumonitis occurs in approximately 1% of patients receiving anti-CTLA-4 therapy and in 4% of patients receiving anti-PD-(L)1 treatment, with around 1% of the cases being severe (34). The gene discussed is CD274; the disease is pneumonitis.